Thanks! You've successfully subscribed to the BONEZONE®/OMTEC® Monthly eNewsletter!

Please take a moment to tell us more about yourself and help us keep unwanted emails out of your inbox.

Choose one or more mailing lists:
BONEZONE/OMTEC Monthly eNewsletter
OMTEC Conference Updates
Advertising/Sponsorship Opportunities
Exhibiting Opportunities
* Indicates a required field.

Orthofix M6-C Artificial Cervical Disc Study: Full 2-Year Data

Orthofix Medical announced full 2-year outcomes from its U.S. Investigational Device Exemption study of the M6-C™ artificial cervical disc vs. anterior cervical discectomy and fusion (ACDF).

Results from the prospective, non-randomized, concurrently controlled clinical trial indicate that patients treated with M6-C had significant improvements in pain, function and quality of life. Further, at 24 months, patients in the ACDF group who were still using pain medications had a seven times higher rate of opioid use than those who received M6-C.

Other study findings included:

  • A statistically significant difference in the average mean surgery time – 74.5 minutes for M6-C procedures vs. 120.2 for ACDF
  • A statistically significant difference in the mean length of hospital stay – 0.61 days for M6-C patients vs. 1.10 days for ACDF patients 
  • Lower subsequent surgery rates at the treated level – 4.8% of ACDF patients compared to 1.9% of M6-C disc patients
  • No device migrations reported
  • A 92% patient satisfaction rate with M6C

The M6-C disc received FDA Premarket Approval in 1Q19 based on the results of this study.

orthofix m6 c cut away

This email address is being protected from spambots. You need JavaScript enabled to view it. is ORTHOWORLD’s Editorial Assistant.